Indications
Ischemic stroke (acute period); ischemic and hemorrhagic stroke (recovery period); traumatic brain injury (acute and recovery period); cognitive impairment in degenerative and vascular diseases of the brain.
$2.00
Active ingredient: | |
---|---|
Dosage form: |
Out of stock
Add to wishlistIschemic stroke (acute period); ischemic and hemorrhagic stroke (recovery period); traumatic brain injury (acute and recovery period); cognitive impairment in degenerative and vascular diseases of the brain.
Vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system); children and adolescents under 18 years of age; hypersensitivity to citicoline.
The solution for oral use is colorless, yellowish or yellowish-brown, transparent.
1 ml | |
of citicoline sodium | 104.5 mg, |
which corresponds to a citicoline content | of 100 mg |
Auxiliary substances:
non-crystallizing liquid sorbitol-200 mg,
anhydrous glycerol-50 mg,
sodium citrate (sodium citrate dihydrate) – 6 mg,
anhydrous citric acid – up to pH 5.0-7.0,
water for injection – up to 1 ml.
The solution for oral use is colorless, yellowish or yellowish-brown, transparent.
1 ml | |
of citicoline sodium | 104.5 mg, |
which corresponds to a citicoline content | of 100 mg |
Auxiliary substances:
non-crystallizing liquid sorbitol-200 mg,
anhydrous glycerol-50 mg,
sodium citrate (sodium citrate dihydrate) – 6 mg,
anhydrous citric acid – up to pH 5.0-7.0,
water for injection – up to 1 ml
Nootropic agent. Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a wide spectrum of action: promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, preventing excessive formation of free radicals, and also prevents cell death by affecting the mechanisms of apoptosis.
In the acute period of stroke, it reduces the volume of damaged tissue, improves cholinergic transmission.
With traumatic brain injury, it reduces the duration of post-traumatic coma and the severity of neurological symptoms.
Citicoline improves the symptoms observed in hypoxia: memory loss, emotional lability, lack of initiative, difficulties in performing daily activities and self-care.
It is effective in the treatment of cognitive, sensory and motor neurological disorders of degenerative and vascular etiology.
Ischemic stroke (acute period); ischemic and hemorrhagic stroke (recovery period); traumatic brain injury (acute and recovery period); cognitive impairment in degenerative and vascular diseases of the brain.
When taken orally-200-300 mg 3 times / day.
IV for strokes and traumatic brain injury in the acute period-1-2 g / day, depending on the severity of the disease for 3-7 days, followed by switching to iv use or oral use.
In / m – 0.5-1 g / day.
Vagotonia (predominance of the tone of the parasympathetic part of the autonomic nervous system); children and adolescents under 18 years of age; hypersensitivity to citicoline.
From the central nervous system and peripheral nervous system: Â insomnia, headache, dizziness, agitation, tremor, numbness in paralyzed limbs.
From the digestive system: Â nausea, decreased appetite, changes in the activity of liver enzymes.
Allergic reactions: Â rash, itchy skin, anaphylactic shock.
Other services: Â fever; in some cases-short-term hypotensive effect, stimulation of the parasympathetic nervous system.
The Citicoline interaction enhances the effects of L-dihydroxyphenylalanine.
Since citicoline is a naturally occurring compound found in the body, a classical pharmacokinetic study cannot be performed due to the complexity of quantifying exogenous and endogenous citicoline.
Citicoline should not be used simultaneously with medications containing meclofenoxate.
Citicoline
By prescription
solution for injection
Out of stock
Reviews
There are no reviews yet